血清γ干扰素诱导蛋白-10和聚乙二醇干扰素治疗HBeAg阳性慢性

StephenW

J Hepatol. <http://www.ncbi.nlm.nih.gov/pubmed/> 2013 Jan 29. pii: S0168-8278(13)00076-7. doi: 10.1016/j.jhep.2013.01.029. [Epub ahead of print]

Serum Levels Of Interferon Gamma-Inducible Protein-10 And Response To Peginterferon Therapy In Hbeag-Positive Chronic Hepatitis B.

Sonneveld MJ, Arends P, Boonstra A, Hansen BE, Janssen HL

Source

Departments of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Abstract

BACKGROUND & AIMS:

Serum levels of interferon-gamma inducible protein 10 (IP-10) are a marker for immune activity, and may predict response to peginterferon (PEG-IFN) therapy in chronic hepatitis B.

METHODS:

IP-10 was measured at baseline and on-treatment week 12 in 210 HBeAg- positive patients treated with PEG-IFN for 52 weeks. Response to treatment was assessed at 6 months post-treatment and defined as HBeAg loss, combined response (HBeAg loss with HBV DNA<10,000c/mL) or HBsAg loss.

RESULTS:

Median baseline IP-10 levels were 158 pg/mL. Higher baseline IP-10 was associated with more HBV DNA, HBeAg and HBsAg decline from week 4 onwards, and IP-10 was higher in patients who achieved HBeAg loss(p=0.001) and combined response (p=0.052). A combination of high IP-10 (>150pg/mL) with absence of precore (PC) and core promoter (BCP) mutants strongly predicted combined response and HBsAg loss: 48% of patients with high IP-10 and no detectable mutants achieved a combined response (p<0.001). A minimal non-significant decline from baseline was observed to week 12 (0.015 log pg/mL,p=0.52 compared to baseline), but decline was somewhat more pronounced in patients who achieved HBeAg loss (0.05 log pg/mL, versus an increase of 0.05 in patients without HBeAg loss,p=0.04).

CONCLUSIONS:

Higher pre-treatment IP-10 levels are associated with an increased probability of HBeAg loss after PEG-IFN therapy. A combination of high baseline IP-10 and absence of PC and BCP mutants identified patients with the highest probability of combined response and HBsAg loss. There appears little use for on-treatment quantification of IP-10 for prediction of response to PEG-IFN.

StephenW

背景与目的：

血清γ-干扰素诱导蛋白10（IP-10）的标记物的免疫活性，并可能预测响应于聚乙二醇（PEG-IFN）治疗慢性乙型肝炎

方法：

IP-10在基线和治疗12周在52周的PEG-IFN治疗的HBeAg阳性患者210。在治疗6个月后对治疗的反应进行了评估，并定义为HBeAg转阴，并结合反应（HBeAg消失HBV DNA <10000 C /毫升）或HBsAg消失。

结果：

中位数基线IP-10水平分别为158 pg / mL的。较高的基准IP-10与更多的HBV DNA，HBeAg和HBsAg下降，从第4周开始，IP-10是患者实现HBeAg消失（P = 0.001）和联合反应（P = 0.052）。高IP-10的结合（> 150pg/mL）没有前C区（PC）和核心启动子（BCP）突变体的强烈预测的响应和HBsAg消失：48％的患者高IP-10没有检测到突变体实现了结合反应（p <0.001）。一个最小的非显着下降，从基线观察到第12周（0.015日志皮克/毫升，P = 0.52与基线相比），但下降的患者实现HBeAg消失（0.05日志皮克/毫升，与增加较为明显0.05患者无HBeAg消失，P = 0.04）。

结论：

较高的预处理IP-10水平与PEG-IFN治疗后HBeAg消失的概率增加。相结合的高基线IP-10和PC和BCP突变体的没有发现患者联合应答和HBsAg消失的概率最高。似乎很少使用的IP-10的预测PEG-IFN对治疗的量化。

硬生生挺起

请问：以您现在对乙肝当前诸多利好消息的了解，比如乙肝受体，判断一下治愈有望吗？是不是还要几十年？

StephenW

回复 硬生生挺起 的帖子

请问：以您现在对乙肝当前诸多利好消息的了解，比如乙肝受体，判断一下治愈有望吗？是不是还要几十年？

我不觉得当前有诸多利好消息. 有进步, 但速度很慢.
乙肝受体的意义是让科学家们建立更好的模型来研究乙肝疾病.
治愈有望吗？当然有望. 现在已经有治疗方法来治愈某些患者. 已经有治疗方法来控制和管理大多数乙肝患者.
治愈是不是还要几十年？我不是一个科学家, 像你们一样，我只能猜测和希望: 在8年内.